Amalgamated Bank Kymera Therapeutics, Inc. Transaction History

Amalgamated Bank

$13.6 Billion
Q3 2025

A detailed history of Amalgamated Bank transactions in Kymera Therapeutics, Inc. stock. As of the latest transaction made, Amalgamated Bank holds 1,626 shares of KYMR stock, worth $103,039. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,626

Previous 1,626 -0.0%

Holding current value

$103,039

Previous $70,000 31.43%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 Apr 25, 2025	BUY	$27.37 - $44.36 $6,377 - $10,335	233 Added 16.73%	1,626 $45,000
Q2 2024 Aug 12, 2024	BUY	$29.85 - $39.42 $2,029 - $2,680	68 Added 5.13%	1,393 $42,000
Q1 2024 Apr 23, 2024	SELL	$22.9 - $43.57 $93,867 - $178,593	-4,099 Reduced 75.57%	1,325 $53,000
Q4 2023 Feb 06, 2024	SELL	$10.97 - $26.84 $4,322 - $10,574	-394 Reduced 6.77%	5,424 $138,000
Q2 2023 Aug 11, 2023	BUY	$22.4 - $34.92 $42,313 - $65,963	1,889 Added 48.08%	5,818 $133,000
Q1 2023 May 02, 2023	SELL	$24.84 - $38.75 $22,927 - $35,766	-923 Reduced 19.02%	3,929 $116,000
Q3 2022 Nov 09, 2022	BUY	$20.91 - $34.27 $1,003 - $1,644	48 Added 1.0%	4,852 $106,000
Q2 2022 Aug 15, 2022	SELL	$14.13 - $42.55 $11,275 - $33,954	-798 Reduced 14.24%	4,804 $95,000
Q1 2022 Jun 30, 2022	SELL	$35.3 - $64.68 $15,390 - $28,200	-436 Reduced 7.22%	5,602 $237,000
Q4 2021 Feb 15, 2022	SELL	$49.91 - $65.56 $3,942 - $5,179	-79 Reduced 1.29%	6,038 $383,000
Q3 2021 Oct 29, 2021	BUY	$47.8 - $66.66 $31,404 - $43,795	657 Added 12.03%	6,117 $359,000
Q2 2021 Aug 16, 2021	BUY	$31.08 - $51.95 $169,696 - $283,647	5,460 New	5,460 $265,000

Others Institutions Holding KYMR

# of Institutions

230

Shares Held

73M

Call Options Held

178K

Put Options Held

64.6K

View Full List

About Kymera Therapeutics, Inc.

Ticker KYMR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 54,705,800
Market Cap $3.47B
Description
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunolo...

More about KYMR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Amalgamated Bank, based on Form 13F filings with the SEC.

News

Stay updated on Amalgamated Bank with notifications on news.

Account

Amalgamated Bank Kymera Therapeutics, Inc. Transaction History